ArticleSynthetic biology (Oxford, England)2019
Expanding the toolbox of synthetic riboswitches with guanine-dependent aptazymes.
Article in Synthetic biology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- High-throughput engineering of ligand-activated splicing ribozyme through domain insertion.bioRxiv : the preprint server for biology · 2026Article
- Development of a tetracycline-inducible programmed ribosomal frameshifting platform for sensitive regulation of mammalian gene expression.Nucleic acids research · 2026Article
- Engineering oxypurinol-responsive riboswitches based on bacterial xanthine aptamers for gene expression control in mammalian cell culture.Nucleic acids research · 2025Article
- Cooperative binding of bivalent ligands yields new insights into the guanidine-II riboswitch.NAR genomics and bioinformatics · 2024Article
- Identification of HDV-like theta ribozymes involved in tRNA-based recoding of gut bacteriophages.Nature communications · 2024Article
- Aptamers' Potential to Fill Therapeutic and Diagnostic Gaps.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A comparative survey of the influence of small self-cleaving ribozymes on gene expression in human cell culture.RNA biology · 2024Article
- Small-Molecule Aptamer for Regulating RNA Functions in Mammalian Cells and Animals.Journal of the American Chemical Society · 2023Article
- Article
- Review
- Lipid membranes modulate the activity of RNA through sequence-dependent interactions.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Efficient splicing-based RNA regulators for tetracycline-inducible gene expression in human cell culture and C. elegans.Nucleic acids research · 2021Article
- Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Guanidine Biosensors Enable Comparison of Cellular Turn-on Kinetics of Riboswitch-Based Biosensor and Reporter.ACS synthetic biology · 2021Article
- High-throughput identification of synthetic riboswitches by barcode-free amplicon-sequencing in human cells.Nature communications · 2020Article
- Massively parallel RNA device engineering in mammalian cells with RNA-Seq.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial riboswitches based on ribozymes serve as versatile tools for ligand-dependent gene expression regulation. Advantages of these so-called aptazymes are their modular architecture and the comparably little coding space they require. A variety of aptamer-ribozyme combinations were constructed in the past 20 years and the resulting aptazymes were applied in diverse contexts in prokaryotic and eukaryotic systems. Most
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.